Implementing a Decentralized Clinical Trial Design for Children with SCN2A & SCN8A Developmental and Epileptic Encephalopathies (DEEs)

contribution from Praxis Precision Medicines

Praxis Precision Medicines is a clinical biopharmaceutical company with the largest portfolio of targeted epilepsy programs. Praxis currently has two ongoing clinical studies for the treatment of pediatric patients with DEEs, the PRAX-222 EMBRAVE Study and the PRAX-562 EMBOLD Study. PRAX-222 is an antisense oligonucleotide (ASO) for early-onset SCN2A-DEE with potential to be the first disease-modifying therapy. PRAX-562 is a potential next generation anti-seizure medication, specially tailored for children with genetic epilepsies.

Behind the Scenes of Praxis Epilepsy studies

At Praxis, passion for developing treatments for children with DEEs runs deep. This video gives insight into why Praxis is so committed to this patient population and why introducing a flexible decentralized clinical trial design for the EMBOLD study is so critical for these patients and their families.

The Praxis EMBOLD study is currently enrolling, to learn more visit www.EMBOLDstudy.org